Founded in 2018, Biointaxis is an academic spin-off company benefiting from extensive know-how in the identification of genes, biomarkers and mechanisms underlying neurodegenerative disorders. Our leading candidate, BTX-101, is currently a novel gene therapy product for the treatment of Friedreich’s Ataxia (FRDA), a rare devastating inherited, progressive, neurodegenerative disease that typically affects teenagers and young adults for whom there are no treatments. Our product proves treatment efficacy being able to re-establish the neurological and cardiac functions.